Scale-ready CDMO Cognate BioServices is a contract development and manufacturing organization specializing in cell and gene therapies with existing manufacturing facilities in the US, UK, and Sweden and a stated revenue range of 25-50 million, signaling capacity for additional development programs and commercial-scale production partnerships.

Clinical-to-Commercial The company offers a broad service spectrum from early preclinical studies through mid-phase trials to product scale-up and commercial manufacturing, providing opportunities to engage customers at various stages of development seeking a single vendor to manage end-to-end manufacturing.

Autologous and Allogeneic Cognate develops both autologous and allogeneic cell therapies across multiple platforms, indicating potential for cross-sell of multiple technology platforms and complementary services to companies pursuing different cell therapy approaches.

Sustainability & Leadership Recent leadership changes in sustainability and HR, along with strategic expansions and a high-profile acquisition history, suggest a company actively investing in governance, talent, and scalable operations, which can be leveraged to position yourself as a growth-support partner.

Expansion & Capacity Historical facility expansions and a July 2022 note on US-based capacity growth imply ongoing demand for manufacturing capacity; there is a sales angle in offering capacity planning, process validation, and supply chain optimization to prospective clients expanding biologics and gene therapy programs.